NEO. NeoGenomics, Inc., together with its subsidiaries, operates a network of cancer-focused genetic testing laboratories in the United States. It operates through Clinical Services and Pharma Services segments. The company laboratories provide genetic and molecular testing services to hospitals, pathologists, oncologists, urologists, other clinicians and researchers, pharmaceutical firms, and other clinical laboratories. It offers cytogenetics testing services to study normal and abnormal chromosomes and their relationship to diseases; fluorescence in-situ hybridization testing services that focus on detecting and locating the presence or absence of specific DNA sequences and genes on chromosomes; flow cytometry testing services to measure the characteristics of cell populations; immunohistochemistry and digital imaging testing services to localize proteins in cells of a tissue section, as well as to allow clients to see and utilize scanned slides, and perform quantitative analysis for various stains; and molecular testing services that focus on the analysis of DNA and RNA, and the structure and function of genes at the molecular level. The company also provides pathology consultation services for clients in which its pathologists review surgical samples on a consultative basis; and testing services in support of its pharmaceutical clients' oncology programs, as well as acts as a reference laboratory supplying anatomic pathology testing services. The company has a strategic alliance with Pharmaceutical Product Development Inc. NeoGenomics, Inc. was founded in 2001 and is headquartered in Fort Myers, Florida.
NOTE: NEO like LXFR and NTWK came out of the MINOLA filter I have in stockfetcher.
TECHNICAL:
4 Days Breakout on previous high of $15.50 reaching a high of $19.00. Possible pullback at $17.00.
NEWS AND CATALYST:
The following are excerpts from yahoo finance.
CHART (1 Year)
CHART (2 Years)
FINVIZ
Finviz has a target of $20.71. Based on its EPS Q/Q of 342% it has a very strong fundamental. Sales Q/Q is not that big which is 8.70%. But with the current news of having beaten estimates with its Q3 Earnings and Revenue, there is a big chance this stock can still soar high.
To see how to enter in this kind of stock, please go to https://excel4stocks.blogspot.com/2019/03/neo-hitting-minola-and-how-to-position.html
NOTE: NEO like LXFR and NTWK came out of the MINOLA filter I have in stockfetcher.
TECHNICAL:
4 Days Breakout on previous high of $15.50 reaching a high of $19.00. Possible pullback at $17.00.
NEWS AND CATALYST:
The following are excerpts from yahoo finance.
October 30, 2018, NEO reported 17% growth in revenue ($69M).
Third Quarter 2018 Highlights:
• 17% increase in consolidated revenue
• 14% increase in clinical genetic testing volume(1)
• 21% increase in Pharma Services revenue; 75% increase in Pharma Services backlog
• Completed $135 million, net equity offering
• Announced acquisition of Genoptix in October for $125 million in cash and 1 million shares of NeoGenomics common stock
CHART (1 Year)
CHART (2 Years)
FINVIZ
Finviz has a target of $20.71. Based on its EPS Q/Q of 342% it has a very strong fundamental. Sales Q/Q is not that big which is 8.70%. But with the current news of having beaten estimates with its Q3 Earnings and Revenue, there is a big chance this stock can still soar high.
BIG CHARTS (NEO in 1 Decade vs NASDAQ).
NEO had a huge divergence against NASDAQ.
BIG CHARTS (NEO in 1 Decade)
STOCKCHARTS.COM (NEO, LXFR, NTWK vs NASDAQ in 3 Years Chart)
As you can see in the comparison against NASDAQ, NEO had gained 187% compared to NASDAQ of 46.64%
STOCKCHARTS.COM (NEO vs NASDAQ in 3 months Chart)
This chart is meant to show the divergence created by NEO against the NASDAQ composite. While NASDAQ broke down on the last week of October 2018, NEO went breaking out of previous high and created new highs.